Navigation Links
Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Announces Successful Interim Analysis of Contrave Light Study
2. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
5. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
6. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
(Date:5/4/2016)... May 4, 2016 According to ... entitled "Brain Computer Interface Market - Global Industry Analysis, Size, ... brain computer interface (BCI) market  is expected to reach ... is estimated to expand at a CAGR of 14.9 ... A BCI device provides collaboration between the ...
(Date:5/4/2016)... -- According to market research "Global Computed Tomography ... 2022 - Industry Insights by Slice Type (High, Mid and ... P&S Market Research, the global computed tomography market ... expected to grow at a CAGR of 5.0% during 2016-2022. ... expected to witness the faster growth, CAGR of 5.3%, during ...
Breaking Medicine Technology:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... conditions and Make-A-Wish grants the most heartfelt wishes of these children. The ... of medical treatment. President and CEO of Make-A-Wish Mississippi, Brent Wilson said, ...
(Date:5/5/2016)... ... ... Long Island’s fastest growing comprehensive eye care provider, North Shore Eye ... Valkenburg, MD as part of their ongoing effort to increase ophthalmic coverage in their ... of North Shore Eye Care. , “We are extremely proud to welcome ...
(Date:5/5/2016)... ... ... TIME for Kids and The ZAC Foundation – a national leader in drowning ... million children with important water safety messages before summer break begins. , ... in children one to 6 years of age. TIME for Kids and The ...
(Date:5/5/2016)... ... , ... In honor of National Nurses Week 2016, Aya Healthcare , ... to thank a nurse who's made a difference in their life. From Friday, May ... Cross of San Diego/Imperial Counties (up to $10,000) every time someone tells them via ...
(Date:5/5/2016)... ... ... Lung Institute will celebrate its three-year anniversary on May 14 by giving away a ... of May. To date, the Lung Institute has treated over 2,000 people at their five ... to the success of this treatment and to the patients who refuse to give up,” ...
Breaking Medicine News(10 mins):